secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-09-03T20:55:07+00:00
Accession:  0001493152-26-041387
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity CEO to present at H.C. Wainwright conference Sept 14-16, 2026
-------------------------------------------------------------------------

- President/CEO Maria Zannes will present corporate update and hold one-on-one investor meetings at H.C. Wainwright 28th Annual Global Investment Conference, Sept 14-16, 2026.
- Presentation to feature CyPath Lung diagnostic test commercial adoption and technology platform advancements for diagnostics and therapeutics.
- As of Sept 2, 2026, company had 600,736 common shares outstanding; aggregate market value ~$5.9M based on Nasdaq closing price.
- Live and archived webcast of presentation available Sept 11 at https://bit.ly/BIAFPresentation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226041387/0001493152-26-041387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226041387/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-041387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer